<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821184</url>
  </required_header>
  <id_info>
    <org_study_id>2006-083</org_study_id>
    <nct_id>NCT00821184</nct_id>
  </id_info>
  <brief_title>Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder</brief_title>
  <official_title>A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help determine if behavior modification performed in conjunction with oral
      Vesicare anticholinergic therapy is more effective for treating overactive bladder symptoms
      than oral Vesicare anticholinergic therapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder symptoms are commonly treated with oral anticholinergic medications that
      work by stopping muscles from tightening or behavioral modification. This study will help
      determine if behavior modification (fluid regulation, pelvic exercises, timed voiding)
      performed in conjunction wth oral Vesicare anticholinergic therapy, is more effective for
      treating overactive bladder symptoms than oral Vesicare anticholinergic therapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient subject availability/findings for data analysis
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Number of Incontinence Episodes Per 24 Hours Measured by Voiding Diaries.</measure>
    <time_frame>0 week - 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Symptom Severity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Vesicare</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vesicare alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vesicare/behavioral modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vesicare plus behavioral modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesicare (solifenacin)</intervention_name>
    <description>5mg po qd</description>
    <arm_group_label>Vesicare</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Vesicare (solifenacin) plus behavioral modification</intervention_name>
    <description>5 mg dose po once daily plus behavioral modification</description>
    <arm_group_label>Vesicare/behavioral modification</arm_group_label>
    <other_name>Vesicare (solifenacin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients &gt; 18 years of age

          -  OAB symptoms for &gt; 3 months

          -  Symptoms defined as greater than 3 episodes/week of an uncontrolled urge to void
             causing incontinence.

          -  May or may not be accompanied by urinary frequency

          -  May be accompanied by stress urinary incontinence where stress incontinence does not
             predominate

        Exclusion Criteria:

          -  Male Patients

          -  Underlying cortical or spinal cord pathology including SCI, MS, or

          -  Parkinson's Disease

          -  Urinary retention with post-void residual &gt; 150cc

          -  Current treatment or treatment within the last 3 months with anticholinergic
             medications

          -  Patients not able to complete the questionaires or voiding diaries in English

          -  Pregnancy

          -  Active urinary tract infections

          -  Bladder Cancer or unevaluated hematuria

          -  Known diagnosis of narrow angle glaucoma

          -  Severe constipation

          -  History of reduced renal function (CrCl&lt;30ml/min)

          -  History of liver disease

          -  Current treatment with cytochrome P450 inhibitor medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John T Stoffel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <results_first_submitted>December 4, 2009</results_first_submitted>
  <results_first_submitted_qc>July 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lahey Clinic</investigator_affiliation>
    <investigator_full_name>Linda Topjian</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <keyword>urinary incontinence</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>urinary frequency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vesicare Alone</title>
          <description>Vesicare alone in treatment of incontinence</description>
        </group>
        <group group_id="P2">
          <title>Vesicare Plus Behavioral Modification</title>
          <description>Vesicare plus behavioral modification for treatment of incontinence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vesicare Alone</title>
          <description>Vesicare alone in treatment of incontinence</description>
        </group>
        <group group_id="B2">
          <title>Vesicare Plus Behavioral Modification</title>
          <description>Vesicare plus behavioral modification for treatment of incontinence</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Number of Incontinence Episodes Per 24 Hours Measured by Voiding Diaries.</title>
        <time_frame>0 week - 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vesicare Alone</title>
            <description>Vesicare alone in treatment of incontinence</description>
          </group>
          <group group_id="O2">
            <title>Vesicare Plus Behavioral Modification</title>
            <description>Vesicare plus behavioral modification for treatment of incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Incontinence Episodes Per 24 Hours Measured by Voiding Diaries.</title>
          <units>incontinence episodes per 24 hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="10" lower_limit="2" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Symptom Severity</title>
        <time_frame>3 months</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Vesicare</title>
            <description>Vesicare alone
Vesicare (solifenacin): 5mg po qd</description>
          </group>
          <group group_id="O2">
            <title>Vesicare/Behavioral Modification</title>
            <description>Vesicare plus behavioral modification
Vesicare (solifenacin) plus behavioral modification: 5 mg dose po once daily plus behavioral modification</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Symptom Severity</title>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vesicare Alone</title>
          <description>Vesicare alone in treatment of incontinence</description>
        </group>
        <group group_id="E2">
          <title>Vesicare Plus Behavioral Modification</title>
          <description>Vesicare plus behavioral modification for treatment of incontinence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John T. Stoffel, MD</name_or_title>
      <organization>Lahey Clinic</organization>
      <phone>781-744-5481</phone>
      <email>John.T.Stoffel@lahey.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

